Literature DB >> 16617275

Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable.

M Alan Brookhart1, Philip S Wang, Daniel H Solomon, Sebastian Schneeweiss.   

Abstract

BACKGROUND: Postmarketing observational studies of the safety and effectiveness of prescription medications are critically important but fraught with methodological problems. The data sources available for such research often lack information on indications and other important confounders for the drug exposure under study. Instrumental variable methods have been proposed as a potential approach to control confounding by indication in nonexperimental studies of treatment effects; however, good instruments are hard to find.
METHODS: We propose an instrument for use in pharmacoepidemiology that is based on a time-varying estimate of the prescribing physician's preference for one drug relative to a competing therapy. The use of this instrument is illustrated in a study comparing the effect of exposure to COX-2 inhibitors with nonselective, nonsteroidal antiinflammatory medications on gastrointestinal complications.
RESULTS: Using conventional multivariable regression adjusting for 17 potential confounders, we found no protective effect due to COX-2 use within 120 days from the initial exposure (risk difference = -0.06 per 100 patients; 95% confidence interval = -0.26 to 0.14). However, the proposed instrumental variable method attributed a protective effect to COX-2 exposure (-1.31 per 100 patients; -2.42 to -0.20) compatible with randomized trial results (-0.65 per 100 patients; -1.08 to -0.22).
CONCLUSIONS: The instrumental variable method that we have proposed appears to have substantially reduced the bias due to unobserved confounding. However, more work needs to be done to understand the sensitivity of this approach to possible violations of the instrumental variable assumptions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16617275      PMCID: PMC2715942          DOI: 10.1097/01.ede.0000193606.58671.c5

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  36 in total

1.  Modeling treatment effects on binary outcomes with grouped-treatment variables and individual covariates.

Authors:  S Claiborne Johnston; Tanya Henneman; Charles E McCulloch; Mark van der Laan
Journal:  Am J Epidemiol       Date:  2002-10-15       Impact factor: 4.897

2.  Risk assessment of drugs, biologics and therapeutic devices: present and future issues.

Authors: 
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003-12       Impact factor: 2.890

3.  Channeling bias in the interpretation of drug effects.

Authors:  H Petri; J Urquhart
Journal:  Stat Med       Date:  1991-04       Impact factor: 2.373

4.  Confounding by indication: the case of calcium channel blockers.

Authors:  M M Joffe
Journal:  Pharmacoepidemiol Drug Saf       Date:  2000-01       Impact factor: 2.890

5.  Confounding by indication.

Authors:  A M Walker
Journal:  Epidemiology       Date:  1996-07       Impact factor: 4.822

6.  Observational studies of drug safety.

Authors:  A M Walker; M J Stampfer
Journal:  Lancet       Date:  1996-08-24       Impact factor: 79.321

7.  Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database.

Authors:  D S Raiford; S Pérez Gutthann; L A García Rodríguez
Journal:  Epidemiology       Date:  1996-01       Impact factor: 4.822

8.  Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context.

Authors:  F H Messerli
Journal:  Ann Intern Med       Date:  1995-12-01       Impact factor: 25.391

9.  The need for randomization in the study of intended effects.

Authors:  O S Miettinen
Journal:  Stat Med       Date:  1983 Apr-Jun       Impact factor: 2.373

10.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

View more
  103 in total

1.  Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses.

Authors:  Jeremy A Rassen; Robert J Glynn; Kenneth J Rothman; Soko Setoguchi; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-12-08       Impact factor: 2.890

2.  Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients.

Authors:  Krista F Huybrechts; M Alan Brookhart; Kenneth J Rothman; Rebecca A Silliman; Tobias Gerhard; Stephen Crystal; Sebastian Schneeweiss
Journal:  Am J Epidemiol       Date:  2011-09-20       Impact factor: 4.897

Review 3.  Healthy user and related biases in observational studies of preventive interventions: a primer for physicians.

Authors:  William H Shrank; Amanda R Patrick; M Alan Brookhart
Journal:  J Gen Intern Med       Date:  2011-01-04       Impact factor: 5.128

4.  Potentially Inappropriate Medication and Health Care Outcomes: An Instrumental Variable Approach.

Authors:  Chi-Chen Chen; Shou-Hsia Cheng
Journal:  Health Serv Res       Date:  2015-11-25       Impact factor: 3.402

5.  Negative controls: a tool for detecting confounding and bias in observational studies.

Authors:  Marc Lipsitch; Eric Tchetgen Tchetgen; Ted Cohen
Journal:  Epidemiology       Date:  2010-05       Impact factor: 4.822

6.  Reference drug programs: effectiveness and policy implications.

Authors:  Sebastian Schneeweiss
Journal:  Health Policy       Date:  2006-06-13       Impact factor: 2.980

7.  Understanding secondary databases: a commentary on "Sources of bias for health state characteristics in secondary databases".

Authors:  Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2007-02-26       Impact factor: 6.437

Review 8.  Developments in post-marketing comparative effectiveness research.

Authors:  S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2007-06-06       Impact factor: 6.875

Review 9.  Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information.

Authors:  Til Stürmer; Robert J Glynn; Kenneth J Rothman; Jerry Avorn; Sebastian Schneeweiss
Journal:  Med Care       Date:  2007-10       Impact factor: 2.983

10.  Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.

Authors:  Rishi J Desai; Mufaddal Mahesri; Younathan Abdia; Julie Barberio; Angela Tong; Dongmu Zhang; Panagiotis Mavros; Seoyoung C Kim; Jessica M Franklin
Journal:  JAMA Netw Open       Date:  2018-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.